The mechanism by which an enzyme used in industrial production of an important drug for type-2 diabetes recognizes its target has been demonstrated by a group of researchers. This finding will further design of novel biocatalysts for industrial production of chiral amine compounds, crucial building blocks in the synthesis of some pharmaceutical drugs.